这家生物技术公司宣布,RGLS8429将成为其新的肾脏疾病候选药物,取代类似的用于常染色体显性多囊肾病(ADPKD)的RG...查看全文
$Regulus Therapeutics(RGLS)$ DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material Accession Number: 0001193125-24-125065 Act: 34 Size: 13 KB 网页链接
$Regulus Therapeutics(RGLS)$ EFFECT Notice of Effectiveness Accession Number: 9999999995-24-001050 Act: 33 Size: 1 KB 网页链接
$Regulus Therapeutics(RGLS)$ DEF 14A Other definitive proxy statements Accession Number: 0001193125-24-102883 Act: 34 Size: 1 MB 网页链接
$Regulus Therapeutics(RGLS)$ ARS Annual Report to Security Holders Accession Number: 0001193125-24-102892 Act: 34 Size: 1 MB 网页链接
$Regulus Therapeutics(RGLS)$ SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals Accession Number: 0000315066-24-001710 Act: 34 Size: 8 KB 网页链接
$Regulus Therapeutics(RGLS)$ S-3 Registration statement under Securities Act of 1933 Accession Number: 0001193125-24-090925 Act: 33 Size: 343 KB 网页链接
$Regulus Therapeutics(RGLS)$ SC 13G Statement of acquisition of beneficial ownership by individuals Accession Number: 0001104659-24-038457 Act: 34 Size: 80 KB 网页链接
$Regulus Therapeutics(RGLS)$ SC 13G Statement of acquisition of beneficial ownership by individuals Accession Number: 0001172661-24-001694 Act: 34 Size: 105 KB 网页链接
$Regulus Therapeutics(RGLS)$ 10-K Annual report [Section 13 and 15(d), not S-K Item 405] Accession Number: 0001628280-24-012543 Act: 34 Size: 7 MB 网页链接
$Regulus Therapeutics(RGLS)$ 8-K Current report, items 2.02 and 9.01 Accession Number: 0001193125-24-073858 Act: 34 Size: 203 KB 网页链接